Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second pivotal, double-blind, placebo-controlled, 8-week study of difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica (NP)

Next Previous
Search
Trial Profile

Second pivotal, double-blind, placebo-controlled, 8-week study of difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica (NP)

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 18 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Difelikefalin (Primary)
  • Indications Pruritus
  • Focus Registrational; Therapeutic Use
  • Acronyms KOURAGE 2

    • Most Recent Events

    • 12 Jun 2024 Status changed from planning to discontinued According to Cara Therapeutics media release.
    • 05 Mar 2024 According to Cara Therapeutics media release, the Company expects final topline results from the first pivotal study are expected by the end of 2025 with the second pivotal study results in early 2026.
    • 25 Jan 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top